教育经历
2010-2012年 美国NIH 眼科研究所 分子免疫 博士后 2009-2010年 美国Nebreska大学 医学中心 肿瘤 博士后 2003-2006年 军事医学科学院 基础医学研究所 免疫学 博士学位 2000-2003年 军事医学科学院 基础医学研究所 免疫学 硕士学位 1995-1999年 河南师范大学 生物系 生物技术 学士学位
◈ 2010-2012: Postdoctor, Molecular Immunology, National Eye Institute, National Institute of Health, MD, USA. ◈ 2009-2010: Postdoctor, Eppley Cancer Institute, Nebraska University Medical Center, NE, USA. ◈ 2003-2006: Ph.D, Molecular Immunology, Beijing Institute of Basic Medical Sciences, Beijing, P.R. China. ◈ 2000-2003: M.S, Molecular Immunology, Beijing Institute of Basic Medical Sciences, Beijing, P.R. China. ◈ 1995-1999: B.S, Department of Biology, Henan normal University, Henan, P.R. China.
工作经历
2019-至今 首都医科大学 北京脑重大疾病研究院 编制外第四层次人才、教授、博士研究生导师 2014-2019年 军事医学科学院 基础医学研究所 免疫学 副研究员 硕士研究生导师 2006-2014年 军事医学科学院 基础医学研究所 免疫学 助理研究员
◈ 2019-present: Professor and lab director in Laboratory of Neuroimmunology, Beijing Institute of Brain Disorders, Capital Medical University. ◈ 2014-2019: Associate Professor, Institute of Basic Medical Sciences, Beijing, P.R. China. ◈ 2006-2014: Assistant Professor, Institute of Basic Medical Sciences, Beijing, P.R. China
研究概述
从事免疫相关疾病特别是脑重大疾病免疫学机制及潜在治疗靶点的研究。研究方向：脑重大疾病发生、发展及治疗的免疫学机制。以前的研究发现实验性自身免疫性葡萄膜炎（EAU）小鼠模型中抑制性细胞因子IL-35降低，而输入外源IL-35可减轻EAU小鼠症状，机制上，IL-35诱导促进能产生IL-35和IL-10的调节性B细胞产生，为寻找新型临床干预策略奠定了理论基础（Nat Med，2014）；发现了一系列新分子如细胞因子IL-39（Eur J Immunol，2016）、异二聚体细胞因子（p28/p40）（J Biol Chem，2012）、 Gm40600 （BMC Cancer，2019）、 Loc108167440 （Leuk Lymphoma，2019）、 BC094916 （Cancer Cell Int，2018），为揭示淋巴细胞分化与功能的细胞与分子调节机制及相关疾病机理奠定了理论基础。针对这些分子作为靶点，探讨这些靶点作为治疗免疫相关疾病(如多发性硬化、葡萄膜炎等)的可行性（Immunology 2021; Front Immunol 2021,2020; Elife 2021; Cell Mol Immunol 2019；Crit Care Med 2018；J Leukoc Biol，2015；J Immunol 2014.等）。共发表SCI论文85篇(如Nat Med, Nat Commun, Cancer Res, Crit Care Med, Cell Mol Immunol, Mol Ther)，总影响因子380余分（单篇最高28.054），他引2500余次（单篇最高400），H指数27。参编专著2部。培养博士后1名、博士研究生6、硕士研究生4名。获国家自然科学基金面上项目3项（2021-2024年，55万元；2018-2021年，60万元；2015-2018年, 70万元），北京市自然科学基金面上项目2项（2018-2020年，20万元；2013-2015年, 14万元），国家科技重大专项项目1项（2014-2016年，555.15万元）；参与军事课题2项，参与国家973课题3项，国家863项目2项，国家自然科学基金面上项目4项。获得授权中国国家发明专利11项和PCT专利2项。兼职中国免疫学会会员，多个SCI杂志编委/审稿人，Czech Science Foundation和国家自然科学基金评审人等。建立了脑重大疾病免疫研究方向，从免疫学方向阐明脑重大疾病发病及治疗机制，扩大脑研究方向与前沿学科交叉，为推进脑研究向纵深发展贡献力量。
His research mainly focuses on immunological mechanisms and potential therapeutic targets of immune-related diseases, especially major brain diseases. He has found that the inhibitory cytokine IL-35 is reduced in the experimental autoimmune uveitis (EAU) mouse model, and the infusion of exogenous IL-35 can alleviate the symptoms of EAU mice. In terms of mechanism, IL-35 induction promotes the production of regulatory B cells that can produce IL-35 and IL-10 has laid a theoretical foundation for the search for new clinical intervention strategies (Nat Med, 2014). He identified a series of new molecules such as the cytokine IL-39 (Eur J Immunol, 2016), heterodimeric cytokines (p28/p40) (J Biol Chem, 2012), Gm40600 (BMC Cancer, 2019), Loc108167440 (Leuk Lymphoma, 2019), BC094916 (Cancer Cell Int, 2018) involved in the cellular and molecular regulation mechanisms of cell differentiation and function and related disease mechanisms. He explored the feasibility of potential targets in the treatment of immune-related diseases (such as multiple sclerosis, uveitis, etc.) (Immunology 2021; Front Immunol 2021,2020; Elife 2021; Cell Mol Immunol 2019; Crit Care Med 2018; J Leukoc Biol, 2015; J Immunol 2014. etc.). He has published a total of 85 SCI papers (such as Nat Med, Nat Commun, Cancer Res, Crit Care Med, Cell Mol Immunol, Mol Ther), with a total impact factor of more than 380 (the highest single article is 28.054), and more than 2500 citations (the highest single article 400), H index 27. He participated in the compilation of 2 monographs. He has instructed 1 post-doctorate, 6 doctoral students, and 4 master students. He got National Natural Science Foundation of China (2021-2024, 550,000 yuan; 2018-2021, 600,000 yuan; 2015-2018, 700,000 yuan), Beijing Natural Science Foundation ( 2018-2020, 200,000 yuan; 2013-2015, 140,000 yuan), national science and technology major special project (2014-2016, 5,551,500 yuan). He participated in 2 military projects, 3 national 973 projects, 2 national 863 projects, and 4 National Natural Science Foundation of China. He obtained 11 authorized Chinese national invention patents and 2 PCT patents. He is a part-time member of the Chinese Society of Immunology, editor/reviewer of multiple SCI journals, reviewer of Czech Science Foundation and National Natural Science Foundation of China. He established the immune research of major brain diseases, clarified the pathogenesis and treatment mechanisms of major brain diseases from the immunology direction, expanded the intersection of brain research directions and cutting-edge disciplines, and contributed to the in-depth development of brain research.
代表成果
一、发表文章 (1).He Y#, Fang Y#, Zhai B#, Liu X#, Zhu G#, Zhou S, Xu Y, Wang X, Su W*, Wang R*. Gm40600 promotes CD4+T cell responses by interacting with Ahnak. Immunology. 2021. Sep. 164:190–206. DOI: 10.1111/imm.13365. (2).Li G, Tang L, Hou C, Wang Z, Gao Y, Dou S, Mo R, Hao Y, Gao Z, Li Y, Dong J, Zhang J, Shen B, Wang R*, Han G*. Peripheral Injection of Tim-3 Antibody Attenuates VSV Encephalitis by Enhancing MHC-I Presentation. Front Immunol. 2021. 12:667478. doi: 10.3389/fimmu.2021.667478. (3).He Y#, Xu R#, Zhai B#, Zhou S, Wang X, Wang R*. Gm614 protects germinal center B cells from death by suppressing caspase-1 transcription in lupus-prone mice. Front Immunol. 2020. 11:585726. doi: 10.3389/fimmu.2020.585726. (4).He Y#, Xu R#, Zhai B#, Fang Y#, Hou C#, Xing C, Xiao H, Chen G, Wang X, Ma N, Han G*, Wang R*. Hspa13 promotes plasma cell production and antibody secretion. Front Immunol. 2020. 11:913. (5).Wei Y#, Zhang F#, Zhang Y#, Wang X, Xing C, Guo J, Zhang H, Suo Z, Li Y, Wang J, Wang R*, Cai Z*. Post-transcriptional regulator Rbm47 elevates IL-10 production and promotes the immunosuppression of B cells. Cell Mol Immunol. 2019 Jun; 16(6):580-589. (6).Sun S#, Jiang Y#, Wang R#, Liu C, Liu X, Song N, Guo Y, Guo R, Du L, Jiang S, Li Y, Qiu Z*, Zhao G*, Zhou Y*. Treatment of paraquat-induced lung injury with an anti-C5a antibody: potential clinical application. Crit Care Med. 2018. May. 46(5): e419-e425. (7).Wang X#, Wei Y#, Xiao H#, Liu X, Zhang Y, Han G, Chen G, Hou C, Ma N, Shen B, Li Y, Egwuagu CE*, Wang R*. Novel IL-23p19/Ebi3 (IL-39) Cytokine Mediates Inflammation in Lupus-like Mice. Eur J Immunol. 2016 Jun; 46(6): 1343-1350. (8).Xing C, Ma N, Xiao H, Wang X, Zheng M, Han G, Chen G, Hou C, Shen B, Li Y*, Wang R*. Critical role for thymic CD19+CD5+CD1dhiIL-10+ regulatory B cells in immune homeostasis. J Leukoc Biol. 2015 Mar; 97(3):547-556. (9).Ma N#, Xing C#, Xiao H#, He Y, Han G, Chen G, Hou C, Marrero B, Wang Y, Zhang S, Shen B, Li Y*, Wang R*. BAFF Suppresses IL-15 Expression in B Cells. J Immunol. 2014. 192: 4192-4201. (10).Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska M, Sergeey YV, Wingfield PT, Kim SH, Egwuagu CE*. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat. Med. 2014. 20: 633-641.
二、专利及其他科研转化成果 (1).Charles Egwuagu, Ren-Xi Wang, Cheng-Rong Yu. METHODS OF PRODUCING AND USING REGULATORY B-CELLS. PCT No.: PCT/US2013/036175. (2).Han G, Chen G, Kang C, Xiao Y, Xie X, Wang R, Lang X, Xiao H, Hou C,Feng J, Jiang X, Zhao Z, Li Y, Shen B. Human Tim-3 fusion protein capable of blocking Tim-3 signaling pathway. PCT No.: PCT/CN2015/000031. (3).王仁喜，肖鹤，韩根成，陈国江，黎燕，沈倍奋，侯春梅，王小茜，魏寅祥，刘晓玲，张玉。P19/Ebi3复合物及其多克隆抗体在系统性红斑狼疮诊治中的应用。专利号：ZL 2015 1 0555637.1。 (4).王仁喜，黎燕，肖鹤，韩根成，陈国江，侯春梅，沈倍奋，马宁，邢陈。一种获得自身反应性B细胞的方法。专利号：ZL 2013 1 0244248.8。 (5).韩根成，陈国江，石新慧，王海滨，肖燕，谢晓玮，肖鹤，王仁喜，王位，冯健男，黎燕，沈倍奋。血清中可溶性Tim-3蛋白作为诊断慢性肾病的标志物。专利号：ZL 2016 1 0292904.5。 (6).陈国江，韩根成，黎燕，沈倍奋，洪海燕，王仁喜，肖鹤，王一，王柯，候春梅。人白介素-1受体拮抗剂的新用途。专利号：ZL 2013 1 0724082.X。 (7).侯春梅，韩根成，陈国江，王仁喜，肖鹤，黎燕，冯健男，沈倍奋。一种基于DNAH5 基因的结肠癌诊断试剂盒。专利号：ZL 2015 1 0070003.7。 (8).韩根成，陈国江，蒋兴伟，王仁喜，肖鹤，侯春梅，于佳卉，赵智，冯健男，黎燕，沈倍奋。一种能阻断Tim-3信号通路的人Tim-3融合蛋白。专利号：ZL 2014 1 0036782.4。 (9).韩根成，陈国江，康春燕，肖燕，谢晓玮，王仁喜，解立新，郎小玲，肖鹤，侯春梅，冯健男，蒋兴伟，赵智，黎燕，沈倍奋。一种检测TIM-3试剂盒及其使用方法。专利号：ZL 2014 1 0036781.X。 (10).王仁喜；黎燕；肖鹤；韩根成；陈国江；侯春梅；沈倍奋；马宁；邢陈。一种治疗多发性硬化的药物组合物。专利号：ZL 2013 1 0120331.4。 (11).王仁喜；黎燕；肖鹤；韩根成；陈国江；侯春梅；沈倍奋；马宁；邢陈。一种治疗系统性红斑狼疮的药物组合物. 专利号：ZL 2013 1 0120334.8. (12).陈国江；韩根成；王仁喜；肖鹤；侯春梅；黎燕；冯建男；沈倍奋；王一；王珂；刘桂君。一种抗肿瘤蛋白质。专利号：ZL 2013 1 0015845. 3. (13).黎燕，沈倍奋，王建安，王仁喜，韩根成，宋伦，钱家华，吴小兵，董小岩，曹晖。用于治疗和预防I型糖尿病的重组腺相关病毒及其用途。专利号：ZL 2003 1 0115504X.
